AgeX Therapeutics to Collaborate with University of California, Irvine on Research Program into Exosome-Based Therapies for Certain Brain Disorders



ALAMEDA, Calif .– (COMMERCIAL THREAD) – AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on the development of therapies for human aging and regeneration, today announced a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the aim of developing therapies to treat the adverse neurocognitive effects of cancer chemotherapy and cancer chemotherapy. radiation therapy on brain function. This research project aims to address a critical unmet medical need that impacts the quality of life of millions of cancer survivors. The agreement between AgeX and the UCI was managed by the UCI Beall Applied Innovation team.

The research will be conducted at the UCI under the supervision of Munjal Acharya, Ph.D., associate professor at the UCI Stem Cell Research Center. Dr Acharya has been working in the field of regenerative medicine and brain damage induced by cancer therapy for 10 years. Currently, Dr. Acharya’s laboratory is studying the molecular and cellular mechanisms of radiation-induced brain damage, regenerative therapies for Alzheimer’s disease and chemobrain.

Exosomes are nanometric-sized extracellular vesicles secreted by cells, which contain a cargo of lipids, proteins and / or nucleic acids, and which participate in communication between cells. Dr Acharya will research exosomes and other extracellular vesicles in samples of cell culture conditioned media used at UCI to derive neural stem cells from AgeX pluripotent stem cells as part of an AgeX sponsored program at research into therapies for Huntington’s disease and other neurological disorders. Using mouse models of brain cancer therapy, Dr. Acharya will determine the safety and efficacy of exosomes or other extracellular vesicles in repairing cognitive impairment and neuroinflammation of the brain induced by radiation therapy and chemotherapy.

“We are excited to collaborate with AgeX to test the efficacy of exosomes derived from a GMP-compliant neural stem cell line that would increase the translational feasibility of our approach to address this unmet medical need facing millions of GMP survivors. cancer in the world, ”said Dr Acharya, UCI.

The collaboration includes an opportunity for AgeX to license inventions that may arise from the research program, and to continue the clinical development and commercialization of therapies derived from these licensed inventions.

“We are delighted to support Dr. Acharya’s efforts to research new therapies for cancer-induced brain damage,” said Dr. Nafees Malik, COO of AgeX. “Dr. Acharya’s work complements the UCI’s efforts in Professor Leslie Thompson’s laboratory which AgeX is sponsoring to develop methods to derive neural stem cells from the pluripotent stem cells of AgeX and its PureStem. .® technology platform for neurological disorders. In addition, we are delighted to expand our involvement in the field of neurology, which has enormous clinical and commercial potential. ”

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on the development and commercialization of innovative therapies to treat human diseases to increase lifespan and combat the effects of aging. AgeX PureStem® and UniverCyte â„¢ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, ready-to-use young cells derived from pluripotent stem cells of any type for application in a variety diseases with a high unmet medical need. AgeX offers two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for type II diabetes. AgeX’s revolutionary Tissue Regeneration-Induced Longevity (iTR â„¢) platform aims to unlock cellular immortality and the regenerative capacity to reverse age-related changes in tissue. HyStem® is AgeX’s delivery technology for stably grafting PureStem or other cell therapy into the body. AgeX is looking for opportunities to establish licensing and collaboration agreements around its vast area of ​​intellectual property, its proprietary technology platforms and its therapeutic product candidates.

For more information, please visit or connect with the company at Twitter, LinkedIn, Facebook and YouTube.

Forward-looking statements

Certain statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements which are not historical facts, including, but not limited to, statements containing Words such as “will”, “” believes “,” anticipates “,” anticipates “,” expects “,” believes “should also be considered as forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and, as such, should be evaluated with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the updates. cautions found in more detail in the “Risk Factors” section of AgeX’s most recent annual report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (copies of which can be obtained at Subsequent events and developments may cause these forward-looking statements to change. In addition, in the case of the UCI exosome research program, there can be no assurance that: (i) any new technology will be invented in the research program, (ii) any new invention will be licensed under conditions commercially favorable, (iii) all resulting products for therapeutic use will be shown to be safe and effective in clinical trials, and (iv) all resulting products developed for therapeutic use will be marketed successfully even if the clinical trials are conclusive. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changes in events or circumstances occurring after the date of this press release, except as required by applicable law.



Comments are closed.